Company / Cash & Equivalents
MARAVAI LIFESCIENCES HOLDINGS, INC. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$216.9M
FY2025
5-year range
$216.9M / $632.1M
FY2022-FY2025
Trend
-32.7%
vs FY2024
Sector context
#80 of 207
Health Care
What the data says
At $217M, MARAVAI LIFESCIENCES HOLDINGS, INC.'s cash & equivalents ranks #80 of 207 in the Health Care sector. Cash & Equivalents has declined for 3 consecutive years, from $632M in FY2022 to $217M in FY2025.
Based on SEC 10-K filings.
$217M in FY2025 with a 3-year CAGR of -30.0%.
Declined from $575M to $217M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -30.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#80 of 207 in Health CareTop 39% of 207This company $216.9M Sector average $669.5M
▼
-67.6% below sector average
Key checks
Key Insights
- MARAVAI LIFESCIENCES HOLDINGS, INC.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -30.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 32.7% year-over-year.
- Ranks #80 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $216.9M | -32.7% |
| FY2024 | $322.4M | -43.9% |
| FY2023 | $575.0M | -9.0% |
| FY2022 | $632.1M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026